How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients?
dc.contributor.author | Yener, Neslihan Parmak | |
dc.contributor.author | Kılınçel, Oğuzhan | |
dc.contributor.author | Gündüz, Cem | |
dc.contributor.buuauthor | Gündüz, Gamze Uçan | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Göz Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAH-6661-2021 | tr_TR |
dc.contributor.scopusid | 57204236887 | tr_TR |
dc.date.accessioned | 2023-11-03T09:59:12Z | |
dc.date.available | 2023-11-03T09:59:12Z | |
dc.date.issued | 2018-05 | |
dc.description.abstract | Purpose: To evaluate anterior segment parameters and intraocular pressure (IOP) modifications in patients using serotonin noradrenaline reuptake inhibitors (SNRIs) due to major depressive disorder. Methods: This cross-sectional study included 170 eyes of 85 subjects. All subjects were divided into three groups: group 1 included 44 healthy control subjects, group 2 included 22 patients receiving antidepressants for 1 week to 6 months, and group 3 included 19 patients receiving antidepressants for >6 months. All subjects underwent a detailed ophthalmologic examination, including gonioscopy. Anterior segments of all subjects were evaluated with the Scheimpflug system and pupil diameter (PD), central corneal thickness, anterior chamber depth (ACD), anterior chamber volume, and anterior chamber angle (ACA) measurements were enrolled. Results: The median IOP was significantly lower in patients using antidepressants [16.0 (11.0-21.0) mmHg] than the control group [17.5 (12.0-21.0) mmHg] (P=0.041). The PD was significantly larger in patients using antidepressants [3.56 (2.29-5.60) mm] than the control group [2.95 (2.00-4.40) mm] (P=0.000). In the study group, PD was also significantly larger in patients using SNRIs for 6 months [3.67 (2.38-5.08) mm] than <6 months [3.31 (2.29-5.60) mm] (P=0.000). The median ACD was significantly lower in patients using antidepressants for 6 months [3.21 (2.52-4.06) mm] than the control group [3.44 (2.63-4.29) mm] (P=0.000). ACAs were measured between 25 degrees and 55 degrees by Scheimpflug imaging. Conclusions: Treatment of SNRIs causes mydriasis and decrease in width of ACD. These changes may not increase IOP as long as the patient has an open angle. SNRIs lead to decrease in IOP particularly in long-term usage. | en_US |
dc.identifier.citation | Gündüz, G. U. vd. (2018). ''How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients?''. Journal of Ocular Pharmacology and Therapeutics, 34(4), 354-359. | en_US |
dc.identifier.endpage | 359 | tr_TR |
dc.identifier.issn | 1080-7683 | |
dc.identifier.issn | 1557-7732 | |
dc.identifier.issue | 4 | tr_TR |
dc.identifier.pubmed | 29446702 | tr_TR |
dc.identifier.scopus | 2-s2.0-85046906129 | tr_TR |
dc.identifier.startpage | 354 | tr_TR |
dc.identifier.uri | https://doi.org/10.1089/jop.2017.0133 | |
dc.identifier.uri | https://www.liebertpub.com/doi/10.1089/jop.2017.0133 | |
dc.identifier.uri | http://hdl.handle.net/11452/34774 | |
dc.identifier.volume | 34 | tr_TR |
dc.identifier.wos | 000425183200001 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Mary Ann Liebert | en_US |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Journal of Ocular Pharmacology and Therapeutics | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Ophthalmology | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Anterior segment parameters | en_US |
dc.subject | Intraocular pressure | en_US |
dc.subject | Serotonin noradrenaline reuptake inhibitors | en_US |
dc.subject | Angle-closure glaucoma | en_US |
dc.subject | Venlafaxine | en_US |
dc.subject | Mechanisms | en_US |
dc.subject | Expression | en_US |
dc.subject | Potent | en_US |
dc.subject | Agents | en_US |
dc.subject.emtree | Duloxetine | en_US |
dc.subject.emtree | Serotonin noradrenalin reuptake inhibitor | en_US |
dc.subject.emtree | Venlafaxine | en_US |
dc.subject.emtree | Antidepressant agent | en_US |
dc.subject.emtree | Duloxetine | en_US |
dc.subject.emtree | Serotonin noradrenalin reuptake inhibitor | en_US |
dc.subject.emtree | Venlafaxine | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Anterior chamber volume | en_US |
dc.subject.emtree | Anterior eye chamber angle | en_US |
dc.subject.emtree | Anterior eye chamber depth | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Central corneal thickness | en_US |
dc.subject.emtree | Clinical evaluation | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Cross-sectional study | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gonioscopy | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Intraocular pressure | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Major depression | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Ophthalmology | en_US |
dc.subject.emtree | Psychopharmacotherapy | en_US |
dc.subject.emtree | Pupil | en_US |
dc.subject.emtree | Visual system parameters | en_US |
dc.subject.emtree | Adolescent | en_US |
dc.subject.emtree | Drug effects | en_US |
dc.subject.emtree | Intraocular pressure | en_US |
dc.subject.emtree | Major depression | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Young adult | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Antidepressive agents | en_US |
dc.subject.mesh | Cross-sectional studies | en_US |
dc.subject.mesh | Depressive disorder, major | en_US |
dc.subject.mesh | Duloxetine hydrochloride | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Intraocular pressure | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Serotonin and noradrenaline reuptake inhibitors | en_US |
dc.subject.mesh | Venlafaxine hydrochloride | en_US |
dc.subject.mesh | Young adult | en_US |
dc.subject.scopus | Bilateral; Angle Closure Glaucoma; Topiramate | en_US |
dc.subject.wos | Ophthalmology | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.title | How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients? | en_US |
dc.type | Article | |
dc.wos.quartile | Q3 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: